Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.240
+0.030 (1.36%)
At close: Feb 21, 2025, 4:00 PM
2.170
-0.070 (-3.13%)
After-hours: Feb 21, 2025, 5:31 PM EST
Innate Pharma Employees
Innate Pharma had 179 employees as of December 31, 2023. The number of employees decreased by 32 or -15.17% compared to the previous year.
Employees
179
Change (1Y)
-32
Growth (1Y)
-15.17%
Revenue / Employee
$202,250
Profits / Employee
-$203,830
Market Cap
192.71M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
IPHA News
- 2 days ago - Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion - Seeking Alpha
- 5 days ago - Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome - Business Wire
- 26 days ago - Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors - Business Wire
- 4 weeks ago - Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York - Business Wire
- 6 weeks ago - Innate Pharma Announces Transformative Strategy to Accelerate Growth - Business Wire
- 2 months ago - Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma - Business Wire
- 2 months ago - Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma - Business Wire